KMDA — Kamada Ltd.

Kamada Limited Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenues: $180.5 million for 2025, up 12% from $161 million in 2024.
• Adjusted EBITDA: $42 million, a 23% increase from $34.1 million in 2024.
• Net Income: $20.2 million ($0.35 per diluted share), a 40% increase from $14.5 million ($0.25 per diluted share) in 2024.
• Cash Position: $75.5 million at year-end, down from $78.4 million in 2024.
• Dividend Declared: $0.25 per share, totaling approximately $14.4 million, payable on April 6, 2026.

2. Strategic Updates and Business Highlights

• Operational Stability: Despite regional geopolitical tensions, Kamada's operations and product manufacturing remain uninterrupted.
• Product Performance: Strong growth in sales of KEDRAB ($54 million) and GLASSIA ($35 million). KEDRAB sales exceeded contract minimums, with a firm commitment of $90 million from Kedrion for 2026-2027.
• New Initiatives: Launch of additional biosimilars in Israel and expansion into the MENA region. Increased plasma collection efforts with two new FDA-approved centers expected to enhance vertical integration and reduce costs.
• Research Programs: Initiation of a comprehensive post-market research program for CYTOGAM to demonstrate its advantages in CMV disease management.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Projected revenues of $200 million to $205 million, representing 13% growth year-over-year.
• Adjusted EBITDA Guidance: Expected between $50 million and $53 million, reflecting a 23% increase from 2025.
• Focus Areas: Continued organic growth through commercialization of FDA-approved products, expansion of distribution, and potential M&A opportunities.

4. Bad News, Challenges, or Points of Concern

• Decline in CYTOGAM Sales: Noted a decrease in revenues due to increased access and usage of competing antivirals, which may impact CYTOGAM's market share.
• Gross Margin Pressure: Slight decline in gross margin (42% in 2025 vs. 43% in 2024) attributed to product mix and increased operating expenses.
• Regulatory Risks: Potential delays in FDA approvals for new plasma collection centers could impact revenue generation timelines.

5. Notable Q&A Insights

• CMV Market Dynamics: Management confirmed no changes in CMV treatment protocols but acknowledged increased access to antivirals affecting CYTOGAM usage. They remain optimistic about the product's necessity and ongoing clinical studies to support its use.
• M&A Strategy: The dividend payment does not indicate a reduction in M&A activity; management is confident in pursuing growth through acquisitions while maintaining shareholder returns.
• Plasma Collection Ramp-Up: Current ramp-up at 30-40% capacity, with full capacity expected by the end of 2027. Initial sales of normal source plasma anticipated in late 2026.
• Biosimilar Launches: Two additional biosimilars expected to launch mid-2026, with sales ramping based on market demand rather than initial stocking orders.

Overall, Kamada reported strong financial performance in 2025, with positive growth outlooks for 2026, despite some challenges in specific product sales and market dynamics.